Acadian Asset Management LLC Sells 91,604 Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Acadian Asset Management LLC trimmed its stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 57.1% in the 2nd quarter, HoldingsChannel reports. The fund owned 68,743 shares of the company’s stock after selling 91,604 shares during the quarter. Acadian Asset Management LLC’s holdings in Tonix Pharmaceuticals were worth $108,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Renaissance Technologies LLC raised its holdings in Tonix Pharmaceuticals by 1.2% in the first quarter. Renaissance Technologies LLC now owns 1,222,424 shares of the company’s stock worth $723,000 after purchasing an additional 14,200 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Tonix Pharmaceuticals by 8.1% during the 4th quarter. Geode Capital Management LLC now owns 371,852 shares of the company’s stock worth $144,000 after acquiring an additional 27,892 shares in the last quarter. Two Sigma Investments LP lifted its position in Tonix Pharmaceuticals by 183.9% during the first quarter. Two Sigma Investments LP now owns 60,191 shares of the company’s stock valued at $36,000 after acquiring an additional 38,991 shares during the last quarter. Virtu Financial LLC boosted its stake in Tonix Pharmaceuticals by 44.8% in the fourth quarter. Virtu Financial LLC now owns 188,075 shares of the company’s stock valued at $73,000 after acquiring an additional 58,184 shares in the last quarter. Finally, UBS Group AG grew its holdings in Tonix Pharmaceuticals by 18,868.5% in the fourth quarter. UBS Group AG now owns 67,528 shares of the company’s stock worth $26,000 after purchasing an additional 67,172 shares during the last quarter. 5.76% of the stock is currently owned by hedge funds and other institutional investors.

Tonix Pharmaceuticals Trading Up 1.4 %

NASDAQ:TNXP opened at $0.48 on Tuesday. The company has a market capitalization of $11.47 million, a P/E ratio of -0.04 and a beta of 2.44. Tonix Pharmaceuticals Holding Corp. has a 12 month low of $0.43 and a 12 month high of $9.81. The firm has a fifty day simple moving average of $0.61 and a 200-day simple moving average of $1.27.

Wall Street Analysts Forecast Growth

TNXP has been the subject of a number of recent analyst reports. Alliance Global Partners lowered their price objective on Tonix Pharmaceuticals from $18.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, August 1st. StockNews.com initiated coverage on Tonix Pharmaceuticals in a research note on Friday. They set a “sell” rating on the stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.